Anti‐tumor immune responses and tumor regression induced with mimotopes of a tumor‐associated T cell epitope

Mimotopes provide an alternative to natural T cell epitopes for cancer immune therapy, as they can recruit and stimulate T cell repertoires that deviate from the repertoires engaged with the tumor and exposed to disease‐related immune suppression. Here, mimotopes of a shared tumor‐associated T cell epitope in cutaneous lymphoma were tested for their capacities to induce clinical and immunological responses in cancer patients. The mimotope sequences had been determined by a combinatorial peptide library approach without knowledge of the corresponding natural tumor‐associated antigen. Vaccination with these mimotopes together with helper T cell‐inducing antigens led to complete tumor remission in the two patients tested. After each booster vaccination, enhanced frequencies of mimotope‐specific CD8+ T cells were detected in the peripheral blood of the patients, and the CTL proved to be cytotoxic and tumoricidal when tested in vitro. These data provide a first indication of clinical efficacy of mimotopes in cancer patients.

[1]  Richard A. Houghten,et al.  Identification of novel antitumor agents from mixture-based synthetic combinatorial libraries using cell-based assays , 1998, Molecular Diversity.

[2]  E. Fiebiger,et al.  Definition of TCR Epitopes for CTL-Mediated Attack of Cutaneous T Cell Lymphoma 1 , 2003, The Journal of Immunology.

[3]  Frank O. Nestle,et al.  Dendritic cells: On the move from bench to bedside , 2001, Nature Medicine.

[4]  R. Houghten,et al.  Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries. , 2001, Blood.

[5]  M. Kalos,et al.  Expression of a Tolerizing Tumor Antigen in Peripheral Tissue Does Not Preclude Recovery of High-Affinity CD8+ T Cells or CTL Immunotherapy of Tumors Expressing the Antigen1 , 2001, The Journal of Immunology.

[6]  S. Rosenberg,et al.  Patients With Melanoma Metastases at Cutaneous and Subcutaneous Sites Are Highly Susceptible to Interleukin-2–Based Therapy , 2001, Journal of immunotherapy.

[7]  Peter Walden,et al.  Mimotopes for tumor‐specific T lymphocytes in human cancer determined with combinatorial peptide libraries , 2001, European journal of immunology.

[8]  B. Seliger,et al.  Antigen-processing machinery breakdown and tumor growth. , 2000, Immunology today.

[9]  R. Willemze.  Primary cutaneous lymphomas , 2000, Current opinion in oncology.

[10]  M. Gavin,et al.  Immunotherapy of human viral and malignant diseases with genetically modified T-cell clones. , 2000, Cancer journal.

[11]  F. Marincola,et al.  Heterogeneity in expression of human leukocyte antigens and melanoma‐associated antigens in advanced melanoma , 2000, Journal of cellular physiology.

[12]  S. Steinberg,et al.  Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. , 1999, Journal of immunology.

[13]  F. Marincola,et al.  Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. , 1999, Journal of immunology.

[14]  S. Riddell,et al.  Deficient cellular immunity--finding and fixing the defects. , 1999, Science.

[15]  Mario Roederer,et al.  Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients , 1999, Nature Medicine.

[16]  K. Sparbier,et al.  T cell receptor specificity and mimotopes. , 1999, Current opinion in immunology.

[17]  L. Chen.  Mimotopes of cytolytic T lymphocytes in cancer immunotherapy. , 1999, Current opinion in immunology.

[18]  R A Houghten,et al.  Exploring immunological specificity using synthetic peptide combinatorial libraries. , 1999, Current opinion in immunology.

[19]  Parkhurst,et al.  Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. , 1999, Journal of immunology.

[20]  R. Dummer,et al.  Immune escape mechanisms in malignant melanoma. , 1999, International journal of molecular medicine.

[21]  S. Rosenberg,et al.  Developing recombinant and synthetic vaccines for the treatment of melanoma. , 1999, Current opinion in oncology.

[22]  J. Schneider-Mergener,et al.  T-cell epitope mapping by flow cytometry , 1998, Nature Medicine.

[23]  A. Lanzavecchia.  Licence to kill , 1998 .

[24]  B. Longley,et al.  Tumor‐specific peptides in cutaneous T‐cell lymphoma: Association with class I major histocompatibility complex and possible derivation from the clonotypic T‐cell receptor , 1998, International journal of cancer.

[25]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[26]  D. Pardoll,et al.  Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Hans-Georg Rammensee,et al.  MHC Ligands and Peptide Motifs , 1998, Molecular Biology Intelligence Unit.

[28]  H. Kerl,et al.  EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. , 1997, Blood.

[29]  K. Asadullah,et al.  Demonstration of frequent occurrence of clonal T cells in the peripheral blood of patients with primary cutaneous T-cell lymphoma. , 1997, Blood.

[30]  Philip J. R. Goulder,et al.  Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.

[31]  S. Kienle,et al.  Self-MHC-restricted peptides recognized by an alloreactive T lymphocyte clone. , 1996, Journal of immunology.

[32]  J. Johnston,et al.  Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes , 1996, The Journal of experimental medicine.

[33]  S. Kienle,et al.  Determination of T cell epitopes with random peptide libraries. , 1996, Journal of immunological methods.

[34]  S. Kienle,et al.  Specificity and degeneracy of minor histocompatibility antigen-specific MHC-restricted CTL. , 1996, Journal of immunology.

[35]  P. Walden,et al.  T-cell epitope determination. , 1996, Current opinion in immunology.

[36]  K. Wiesmüller,et al.  Elucidation of T-cell epitopes: a synthetic approach with random peptide libraries. , 1995, Biochemical Society transactions.

[37]  K. Wiesmüller,et al.  Efficacy of synthetic vaccines in the induction of cytotoxic T lymphocytes. Comparison of the costimulating support provided by helper T cells and lipoamino acid. , 1994, Journal of immunological methods.

[38]  V. Gnau,et al.  Analysis of a naturally occurring HLA class I-restricted viral epitope. , 1994, Immunology.

[39]  P. Singer.  Licence to kill , 1994, Nature.

[40]  P. Walden,et al.  Collaboration of helper and cytotoxic T lymphocytes , 1993, European journal of immunology.

[41]  J. D. de Vries,et al.  Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells. I. In vitro generation, isolation, and analysis to phenotype and specificity. , 1984, Journal of immunology.